Myasthenia gravis: open trials in Belgium

11 open trials have a site in Belgium. Registry data; only the trial team decides who can take part.

NCT04951622
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Hopital Erasme, Anderlecht · Az St-Jan Brugge-Oostende A.V., Brugge · AZ Sint-Lucas & Volkskliniek, Gent · UZ Leuven, Leuven · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-11-05
NCT07673627
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Trial Treatment · Phase 2 · argenx
UZ Leuven, Leuven · Centre Hospitalier Regional de la Citadelle, Liège
Registry updated 2026-11-04
NCT05374590
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Trial Treatment · Phase 2/3 · argenx
Antwerp University Hospital, Edegem · Universitair Ziekenhuis Gent, Gent
Registry updated 2026-11-03
NCT07294170
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Research · argenx
UZ Leuven - PPDS, Leuven · Hôpital de la Citadelle, Liège
Registry updated 2026-10-26
NCT06463587
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Trial Treatment · Phase 3 · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
UZ Leuven, Leuven · Centre Hospitalier Regional de la Citadelle, Liège
Registry updated 2026-10-21
NCT06392386
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Trial Treatment · Phase 2/3 · argenx
Universitair Ziekenhuis Gent, Gent
Registry updated 2026-09-28
NCT07284420
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Trial Treatment · Phase 2 · argenx
UZ Leuven, Leuven · Centre Hospitalier Regional de la Citadelle, Liège
Registry updated 2026-09-24
NCT06414954
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Trial Treatment · Phase 2 · NMD Pharma A/S
UZ Leuven, Leuven
Registry updated 2026-08-21
2023-507539-40-00
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
Trial Treatment · Phase 2 · NMD Pharma A/S
UZ Leuven, Leuven
Registry updated 2026-02-26
NCT06298565
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Research · argenx
UZ Leuven (University Hospitals Leuven), Leuven
Registry updated 2026-02-17
NCT07136844
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Trial Treatment · Centre Hospitalier Universitaire de Liege
Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle, Liège
Registry updated 2025-08-22

All Myasthenia gravis trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error